卡铂联合紫杉醇腹腔化疗对高级别浆液性卵巢癌的疗效

doi:10.3969/j.issn.2095-9400.2021.07.011

Abstract
Figure/Table
References (13)
Related Citation (7)

Download: PDF (1261 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the curative effect of carboplatin/paclitaxel intraperitoneal chemotherapy on high-grade serous ovarian cancer (HGSOC). Methods: According to the diagnostic result given by senior pathologists from our hospital, 110 cases of the most typical high-grade serous ovarian cancer were selected from numerous gynecological tumor slices of the First Affiliated Hospital of Wenzhou Medical University from January 2015 to July 2019. Considering their clinical data, these patients were assigned to four groups. Group A included 34 patients treated by paclitaxel combined with carboplatin intravenous chemotherapy;group B was 30 patients by paclitaxel combined carboplatin intraperitoneal chemotherapy; group C included 28 patients by paclitaxel combined with cisplatin intraperitoneal chemotherapy and group D was intravenous group,including 18 patients treated with traditional chemotherapy drugs (cyclophosphamide, adriamycin, etc.). The effectiveness and safety of carboplatin /paclitaxel intraperitoneal chemotherapy in high-grade serous ovarian cancer (HGSOC) were evaluated by comparing the four groups in the survival rate and side effects. Results: The 5-year survival rate of group A, group B, and group C was significantly higher than that of group D, with statistical difference between each group (P<0.05). The 3-year survival rate of group B and C was also higher than that of group D, with statistical difference between the groups (P<0.05).However, the 3-year and 5-year survival rates between groups A, B, and C showed no statistical difference (P>0.05).The incidence of grade III, IV bone marrow suppression was the highest in group D without significant difference among the four groups (P>0.05). The incidence of grade III, IV gastrointestinal reactions and abdominal pain was significantly different (P<0.05), but with no difference either between group A and group B or between group C and group D (P>0.05). And there was no significant difference in the incidence of rash among the four groups (P>0.05). Conclusion: Compared with cisplatin, carboplatin combined with paclitaxel intraperitoneal chemotherapy can prolong the survival time of patients with HGSOC, improve the treatment effectiveness and have fewer side effects, which can provide reference for future clinical chemotherapy.

Key words： high-grade serous ovarian cancer intraperitoneal chemotherapy carboplatin paclitaxel survival rate

Received: 09 September 2020

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Lai Ze
	Zou Ruanmin
	Yuan Zongjie
	TU Xinyu
	Zhang Junwei
	Huang Jiaheng
	Xue Xiangyang

URL:

https://xb.wmu.edu.cn/EN/10.3969/j.issn.2095-9400.2021.07.011 OR https://xb.wmu.edu.cn/EN/Y2021/V51/I7/578

[1] 周路, 余征, 覃强, 等. 卵巢癌组织中FGF8b表达与EMT的关系及临床意义[J]. 临床肿瘤学杂志, 2020, 25(6): 532-537.
[2] LI L, BI X, SUN H, et al. Characterization of ovarian cancer cells and tissues by Fourier transform infrared spectroscopy[J]. J Ovarian Res, 2018, 11(1): 64.
[3] ORR B, EDWARDS R P. Diagnosis and treatment of ovarian cancer[J]. Hematol Oncol Clin North Am, 2018, 32(6): 943-964.
[4] MAHMOOD R D, MORGAN R D, EDMONDSON R J, et al.First-Line management of advanced high-grade serous ovarian cancer[J]. Curr Oncol Rep, 2020, 22(6): 64.
[5] KOH W J, ABU-RUSTUM N R, BEAN S, et al. Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2019, 17(1): 64-84.
[6] WEBB P M, JORDAN S J. Epidemiology of epithelial ovarian cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2017, 41:3-14.
[7] MATULONIS U A, SOOD A K, FALLOWFIELD L, et al.Ovarian cancer[J]. Nat Rev Dis Primers, 2016, 2: 16061.
[8] STEWART C, RALYEA C, LOCKWOOD S. Ovarian cancer:an integrated review[J]. Semin Oncol Nurs, 2019, 35(2):151-156.
[9] VAN DRIEL W J, KOOLE S N, SIKORSKA K, et al.Hyperthermic intraperitoneal chemotherapy in ovarian cancer[J]. N Engl J Med, 2018, 378(3): 230-240.
[10] 韩冰, 赵倩, 海盼盼, 等. 卡铂腹腔化疗在晚期卵巢癌患者中的应用研究[J]. 中国妇产科临床杂志, 2020, 21(3): 269-271.
[11] OSWALD A J, GOURLEY C. Intraperitoneal chemotherapy:historic anomaly or hope for the future?[J]. Clin Oncol (R Coll Radiol), 2018, 30(8): 484-492.
[12] PROVENCHER D M, GALLAGHER C J, PARULEKAR W R, et al. OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer[J]. Ann Oncol, 2018, 29(2): 431-438.
[13] WALKER J L, BRADY M F, WENZEL L, et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study[J]. J Clin Oncol, 2019, 37(16): 1380-1390.